GlaxoSmithKline's Nucala beats AZ's Fasenra to the IL-5 punch in nasal polyps

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Jul 29, 2021 at 11:12 PM.

  1. cafead

    cafead Administrator
    Staff Member

    Joined:
    Nov 21, 2001
    Messages:
    32,746
    Likes Received:
    3
    via GlaxoSmithKline’s antibody drug Nucala may not have been the first biologic approved in nasal polyps—that distinction goes to Sanofi and Regeneron’s Dupixent. But on Thursday, it did become the first IL-5 inhibitor to break into the indication, notching a win over AstraZeneca’s would-be rival Fasenra.

    article source